Related Experiment Video
Updated: Aug 10, 2026
Preparation and Pathogen Inactivation of Double Dose Buffy Coat Platelet Products using the INTERCEPT Blood System
Published on: December 7, 2012
Pentoxifylline and intravenous gamma globulin combination therapy for acute Kawasaki disease
S Furukawa1, T Matsubara, Y Umezawa
1Department of Paediatrics, Yamaguchi University School of Medicine, Japan.
Insights
High-dose pentoxifylline (PTX) combined with intravenous gamma globulin (IVGG) significantly reduced coronary artery lesions in children with Kawasaki disease (KD). Standard IVGG therapy showed no significant difference compared to low-dose PTX and IVGG combination therapy.
Area of Science:
- Pediatrics
- Cardiology
- Pharmacology
Background:
- Kawasaki disease (KD) is a pediatric illness causing inflammation in blood vessels, potentially leading to coronary artery lesions (CAL).
- Intravenous gamma globulin (IVGG) is a standard treatment for KD, but alternative or adjunctive therapies are explored to improve outcomes.
Purpose of the Study:
- To evaluate the efficacy of oral pentoxifylline (PTX) combined with IVGG in preventing CAL in children with KD.
- To compare high-dose and low-dose PTX combination therapies against standard IVGG treatment.
Main Methods:
- A randomized trial involving children with KD, all initially free from CAL.
- Patients received standard care including acetylsalicylic acid and IVGG, with experimental groups receiving additional oral PTX (10mg/kg or 20mg/kg daily).
- Coronary artery lesions were assessed using two-dimensional echocardiography throughout the study period.
Main Results:
- High-dose PTX and IVGG combination therapy showed a statistically significant reduction in CAL (0%) compared to IVGG alone (14.3%).
- Low-dose PTX and IVGG combination therapy did not show a significant difference in CAL rates compared to IVGG alone (11.1% vs 16.7%).
- No adverse side effects were reported in any of the 79 participating patients.
Conclusions:
- High-dose oral pentoxifylline as an adjunct to IVGG is effective in preventing coronary artery lesions in children with Kawasaki disease.
- Further research may support high-dose PTX and IVGG combination therapy as a superior treatment strategy for KD.
- The safety profile of PTX in combination with IVGG for KD treatment appears favorable.
Abstract:
We compared the efficacy of oral administration of pentoxifylline (PTX) and intravenous infusions of gamma globulin (IVGG) combination therapy with that of IVGG in reducing the frequency of coronary-artery lesions (CAL) in children with Kawasaki disease (KD), in a randomized trial. All patients with KD received acetylsalicylic acid (30 mg/kg per day), until the 30th day, after the onset of fever, followed by daily acetylsalicylic acid at a dose of 3-5 mg/kg per day there-after, and intravenous IVGG, 200 mg/kg per day, for 5 consecutive days. In addition, patients randomly assigned to PTX and IVGG combination therapy groups received oral PTX at a dosage of 10 mg/kg per day (low-dose) or 20 mg/kg per day (high-dose), in three divided doses until the 30th day. Patients with KD were all free from CAL prior to treatment. We assessed the presence of CAL by two-dimensional echocardiography which was also done prior to treatment and then twice a week after hospital admission. We detected CAL in 3 of 18 patients (16.7%) in the IVGG therapy group, as compared with 2 of 18 patients (11.1%) in the low-dose PTX and IVGG combination therapy group. There were no significant difference between the two groups. In the next study, we detected CAL in 3 of 21 patients (14.3%) in the IVGG therapy group, as compared with none of 22 patients (0%) in the high-dose PTX and IVGG combination therapy group (chi 2 = 6.4, P < 0.02). No adverse side-effects were observed in 79 patients with KD.(ABSTRACT TRUNCATED AT 250 WORDS)
Related Concept Videos
01:23Treatment for Pulmonary Arterial Hypertension: Prostacyclin Receptor Agonists
These agonists bind to the IPR receptor situated on the plasma membrane of the pulmonary artery smooth muscle cells. This binding triggers a cascade of reactions known as the GS-AC-cAMP-PKA pathway. This pathway results in the relaxation of smooth muscle...
01:28Pneumonia IV: Management
Bacterial Pneumonia Treatment
For bacterial pneumonia, antibiotics serve as the cornerstone of therapy. Initial treatment often begins with empirical antibiotics, tailored to the anticipated causative organism and adjusted based on culture results. Key antibiotic choices include:
01:28Pulmonary Tuberculosis V
Latent tuberculosis infection occurs when TB bacteria are present in a person's body, but are not causing illness or symptoms. It is not contagious, and preventive treatment is crucial to avoid the progression...
01:26Pharmaceutical Poisoning: Treatment Strategies
01:22Myocarditis IV: Nursing Management
01:29Venous Thrombosis III: Interprofessional Care